IL DONG PHARMACEUTICAL CO., LTD. Logo

IL DONG PHARMACEUTICAL CO., LTD.

Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.

249420 | KO

Overview

Corporate Details

ISIN(s):
KR7249420001
LEI:
Country:
South Korea
Address:
서울특별시 서초구 바우뫼로27길 2, 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IL DONG PHARMACEUTICAL CO., LTD. is a healthcare company specializing in the research, development, manufacturing, and commercialization of pharmaceutical products. The company's business spans finished drugs, active pharmaceutical ingredients (APIs), and contract manufacturing (CMO) services, utilizing its GMP-certified facilities. Its therapeutic focus includes metabolic disorders, respiratory diseases, oncology, cardiovascular conditions, and gastrointestinal diseases. Ildong Pharmaceutical is committed to innovation, advancing a robust pipeline of novel drug candidates such as oral GLP-1 agonists for diabetes/obesity and first-in-class treatments for fibrotic diseases, partly through its spin-off iLeadBMS. The company is actively expanding its global market presence through strategic partnerships, licensing, and exports.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 129.5 KB
2025-09-11 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 42.4 KB
2025-09-09 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.5 MB
2025-07-30 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 16.9 KB
2025-07-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-07-30 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.2 KB
2025-07-30 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 18.4 KB
2025-07-28 00:00
Report Publication Announcement
결산실적공시예고(안내공시)
Korean 4.4 KB
2025-07-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 61.3 KB
2025-07-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 69.4 KB
2025-07-14 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.8 KB
2025-07-08 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.3 KB
2025-07-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 136.4 KB
2025-07-08 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 48.3 KB

Automate Your Workflow. Get a real-time feed of all IL DONG PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IL DONG PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IL DONG PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.